Read summaries from the IPC symposium at the 2026 Society for Investigative Dermatology (SID) Annual Meeting covering disease modification, immune pathways, therapeutic escape, and psoriasis treatment response.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
The International Psoriasis Council (IPC) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have launched a global consensus initiative to define difficult-to-treat and treatment-refractory psoriasis, with the goal of improving clinical care, research consistency, and treatment decision-making worldwide.
This commentary from IPC Board Member Lluís Puig examines inference-based guidance for managing immune checkpoint inhibitor-induced psoriasis and discusses how biologics and targeted systemic therapies can be used safely alongside cancer immunotherapy.
This expert overview by IPC Junior Councilor María Julia Cura examines palmoplantar pustulosis as a distinct inflammatory disease with evolving therapeutic implications.
Jason Hawkes provides expert commentary on an international multicenter study evaluating two-year drug survival, efficacy, and safety of acitretin, cyclosporine, and methotrexate in pediatric psoriasis patients.
Artificial intelligence is transforming psoriasis care by improving diagnosis accuracy, guiding treatment decisions, and supporting personalized management.
The 2025 ESDR Congress in Antwerp brought together over 1,000 dermatology researchers. This report summarizes the latest psoriasis research, including immune shifts, paradoxical psoriasis, drug-induced cases, topical and oral treatments, and innovative abstracts.
At the 2025 EADV Annual Meeting in Paris, experts shared new insights into psoriasis diagnosis, symptoms, and treatment. Highlights include the IPC Symposium, Free Communication sessions, and results from pivotal clinical trials on emerging oral peptides, IL-23 inhibitors, and dose-optimization strategies.
IPC Councilor Dr. Matias Maskin provides expert commentary on a recent study linking TNF-alpha inhibitors to lower psoriatic arthritis risk in severe psoriasis. This ten-year study compares biologics with phototherapy.
IPC publishes a global review highlighting the physical, emotional, and family burden of pediatric psoriasis. Read the full findings and download the report.
IPC Councilor Dr. Tiago Torres provides expert commentary on research linking psoriasis severity to cardiovascular disease via systemic inflammation. The study identifies GlycA as a key biomarker partially mediating this connection using robust mediation models and data from US and Swedish cohorts. Learn how these findings support a systemic view of psoriasis and its implications for cardiovascular risk management.
How can clinicians navigate emotionally complex patient interactions while maintaining empathy and trust? In this article, Mio Nakamura discusses communication approaches that may help strengthen patient relationships in dermatology settings.
Read summaries from the IPC symposium at the 2026 Society for Investigative Dermatology (SID) Annual Meeting covering disease modification, immune pathways, therapeutic escape, and psoriasis treatment response.
In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of systemic corticosteroids in psoriasis. He questions whether they contraindicate the treatment of psoriasis, while also covering his personal experience in prescribing them.
In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of topical corticosteroids in psoriasis, covering current use, guidelines, and consequences.
Missed the joint symposium hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the American Academy of Dermatology (AAD) Annual Meeting? Select presentations from Psoriasis or Dermatitis? When Boundaries Blur and Treatments Flip the Script are now available, covering diagnostic overlap, emerging tools, treatment-related reactions, and practical strategies for managing complex cases across diverse patient populations.
